Pfizer Inc. $PFE Stock: Profund Advisors LLC Raises Position

Profund Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 59.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 117,159 shares of the biopharmaceutical company’s stock after purchasing an additional 43,778 shares during the period. Profund Advisors LLC’s holdings in Pfizer were worth $3,341,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ProShare Advisors LLC boosted its holdings in shares of Pfizer by 1.6% during the 3rd quarter. ProShare Advisors LLC now owns 920,410 shares of the biopharmaceutical company’s stock worth $26,250,000 after buying an additional 14,321 shares during the period. Vise Technologies Inc. raised its holdings in Pfizer by 16.0% in the 3rd quarter. Vise Technologies Inc. now owns 364,384 shares of the biopharmaceutical company’s stock worth $10,392,000 after acquiring an additional 50,231 shares during the period. Grandfield & Dodd LLC raised its holdings in Pfizer by 2.3% in the 3rd quarter. Grandfield & Dodd LLC now owns 48,815 shares of the biopharmaceutical company’s stock worth $1,392,000 after acquiring an additional 1,094 shares during the period. Investment Partners LTD. lifted its position in Pfizer by 105.9% during the 3rd quarter. Investment Partners LTD. now owns 33,323 shares of the biopharmaceutical company’s stock worth $950,000 after acquiring an additional 17,140 shares during the last quarter. Finally, Cidel Asset Management Inc. lifted its position in Pfizer by 2.1% during the 3rd quarter. Cidel Asset Management Inc. now owns 100,009 shares of the biopharmaceutical company’s stock worth $2,852,000 after acquiring an additional 2,068 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $30.48 on Monday. The stock has a market cap of $173.73 billion, a P/E ratio of 40.11, a PEG ratio of 2.07 and a beta of 0.31. Pfizer Inc. has a one year low of $23.62 and a one year high of $30.67. The company has a fifty day moving average price of $28.55 and a 200 day moving average price of $26.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Cantor Fitzgerald lifted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.65.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.